

Efficacy of Pulsed Electromagnetic Field Therapy for Treatment of Canine Osteoarthritis

Aimee M. Krebsbach^a, Peter H. Eeg^b

^a Caerus Corp, Arden Hills, MN 55112, USA

^b Poolesville Veterinary Clinic, Poolesville, MD 20837, USA

ABSTRACT

Canine osteoarthritis affects roughly one in four dogs, causing loss of function that ranges from joint pain to lameness. Standard drug therapy for this disease carries a variety of potential side effects and long-term treatment requires routine metabolic blood panels. Pulsed electromagnetic fields are emerging as a drug-free pain relief therapy alternative or adjunct for various treatment protocols. This collective case study examined their effectiveness in the form of the EMbrace Relief System for canine osteoarthritis application. It was found that the device effectively reduced pain and symptoms of osteoarthritis in the study group over time based on data collected. This study shows promising results supporting the use of pulsed electromagnetic fields for canine osteoarthritis treatment.

INTRODUCTION

Canine osteoarthritis (OA) is a chronic degenerative disease which causes joint pain, stiffness, swelling, and progressive weakness. These signs are a result of cartilage damage, osteophytes, and capsular swelling, leading to deterioration of function. OA affects approximately 20% of the adult canine population, with older dogs and large breeds being at an even higher risk.¹ Hip dysplasia is also a sequela of OA and affects 16% of canines in the United States.² Traditional therapy for OA is dominated by pharmaceuticals, specifically non-steroidal anti-inflammatory drugs (NSAIDs) and, to a lesser extent, steroids. These varieties of drug treatment are accompanied by a host of potential side effects including ulceration, vomiting, abdominal pain, weight gain, osteoporosis, high blood sugar, cataracts, suppressed immune system, fluid retention, liver and kidney disease, increased risk of heart disease, aseptic necrosis, and cartilage degradation from decreased collagen production.¹ Due to these staggering potential side effects, alternative therapies are emerging for the treatment of OA. Low frequency pulsed electromagnetic field (PEMF) therapy restores cellular potential, activates endorphins, and increases blood and lymph flow to relieve pain and inflammation. PEMF has been proven effective in human applications and has begun to gain veterinary prominence.³ This study investigated the efficacy of the EMbrace Relief System by Caerus Corp, a garment with attachable PEMF delivery units that target regions where canine OA is most common: the hips, back, and shoulders.⁴ Over the course of 5 weeks, participants were monitored in a collective case study to assess the effectiveness of PEMF in aiding canine OA.

METHODS

STUDY DESIGN

The present study was conducted using a single-center, prospective, observational, collective case design. The study followed 8 canine participants over the course of 5 weeks. Each participant used the device according to veterinary advice throughout the duration of the study. Canine owners observed participant behavior over the course of the 5 weeks with weekly data collection. Data consisted of an owner's assessment of the participant's state using the Helsinki Chronic Pain Index (HCPI) and Canine Brief Pain Inventory (CBPI).

PARTICIPANTS

There were 8 canine participants included in the study. Weight ranged from 34 to 159 pounds with a mean of 67.6 pounds. Ages ranged from 6 to 16 years with a mean of 12.8 years. Of the participants, 5 were male and 3 were female. As this study was not an experimental design, outside variables related to health were present. Participants experienced and documented a variety of conditions and therapies throughout the course of the study that were not considered upon analysis and interpretation of study results. As a control, all study patients maintained their active therapies without alteration or addition for the duration of the study.

HELSINKI CHRONIC PAIN INDEX

The HCPI is a scoring system proven in 2009 to be a valid, reliable, and responsive tool for assessment of response to treatment in dogs with OA.⁵ The index consists of 11 items based on a simple descriptive scale for demeanor, behavior, and locomotion as well as a visual analog scale for pain and locomotion.⁶ Items include: attitude and/or mood, willingness to participate in play or interact, frequency in vocalization or discomfort behavior, eagerness to walk, ability and/or willingness to walk up and/or down stairs, ability and/or willingness to run, ability and/or willingness to jump, ease in lying down, ease in rising from a down position, ease of movement after a long rest, and ease of movement during and/or after exercise/walks. Each item has a scoring scale from 0 to 4, where 0 represents the least pain (i.e. very willing, very eager, etc.) and 4 represents the most pain (i.e. does not jump at all, very difficult, etc.). Canine owners recorded weekly scores based on participant observation for 5 weeks.

CANINE BRIEF PAIN INVENTORY

The CBPI is a scoring system proven in 2007 to obtain quantifiable assessments regarding the severity and impact of chronic pain and treatment for dogs with osteoarthritis.^{7,8} The inventory consists of 11 items involving pain severity, pain interference with function, and quality of life.⁶ Items include: worst pain in last 7 days, least pain in last 7 days, average pain in last 7 days, current pain, general activity, enjoyment of life, ability to rise to standing from lying down, ability to walk, ability to run, ability to climb, and overall impression. Items are scored on a scale of 0 to 10 where 0 represents no pain or interference and 10 represents severe pain or complete interference. Canine owners recorded weekly scores based on participant observation for 5 weeks.

ANALYSIS

Data from all participants was gathered, randomized, and grouped by scoring system. To investigate the primary outcome of group improvement over time, the week's scores from each scoring system were grouped together. A paired sample t-test was conducted to compare means of these groups from baseline and endpoint as well as week to week progression. A one-tailed p-value of <0.01 indicates significant difference in group means. Item 11 of the CBPI, "overall impression", was excluded from analysis, as its ranking scale is opposite that of all other items. For analysis of the secondary outcome, individual improvement over time, scores for each participant were grouped by week and scoring system. A paired sample t-test was conducted to compare means of each

participant from baseline and endpoint for both scoring systems. Due to a death that resulted from outside health conditions, one participant's data was omitted from analysis.

RESULTS

As a group, significant improvement of scores was seen for both scoring systems. The HCPI scoring group means significantly improved from baseline (week 1) to week 2, week 2 to week 3, week 3 to week 4, and baseline to endpoint (week 5). The CBPI scoring group means significantly improved from baseline to week 2, week 2 to week 3, week 3 to week 4, week 4 to endpoint, and baseline to endpoint. These primary outcome results can be seen in Figure 1 below. The secondary outcome, individual improvement over time, also saw promising results. It was found that 3 participants had significantly improved scores for both scoring systems from baseline to endpoint, 3 participants had significantly improved scores for one of the scoring systems, and only 1 participant did not have a significantly improved score for either scoring system ($p < 0.01$).




Figure 1: Mean scores over time from baseline to endpoint for CBPI (A) and HCPI (B). (* indicates $p < 0.01$)

DISCUSSION

Based on the progression of significantly reduced mean scores over the 5-week study duration, the participant group demonstrated improvement in the outcomes measured by both systems. The measurement systems at hand have been proven valid for assessment of OA-related pain reduction and treatment response, indicating that the PEMF device was effective in treating OA in the study group. Limitations did exist in this study. As discussed, outside health-related variables were omitted due to the nature of the study design. Additionally, the quantitative data was based on observational and subjective reporting. Finally, data reporting was limited by the items contained in the measurement systems and number of participants. While these variables are important to note, the robust and consistent significance of all data pertaining to both the primary and secondary outcomes supports a conclusion that Caerus Corp's EMbrace Relief System is effective in treating pain and major signs

related to canine OA. These results show promising evidence for application of PEMF as a safe, effective, and drug-free veterinary therapy.

REFERENCES

- [1] S. Bland. Canine Osteoarthritis and Treatments: A Review. *Veterinary Science Development*. 5 (2015) 84-89.
- [2] R. Loder, R. Todhunter. The Demographics of Canine Hip Dysplasia in the United States and Canada. *Journal of Veterinary Medicine*. 2017:5723476 (2017) 15 pages.
- [3] S. Pinna, F. Landucci, A.M. Tribuiani, F. Carli, A. Venturini. The Effects of Pulsed Electromagnetic Field in the Treatment of Osteoarthritis in Dogs: Clinical Study. *Pakistan Veterinary Journal*. 33 (2012) 96-100.
- [4] Osteoarthritis in Dogs. American College of Veterinary Surgeons. (2019).
- [5] A. Hielm-Björkman, H. Rita, R.M. Tulamo. Psychometric Testing of the Helsinki Chronic Pain Index by Completion of a Questionnaire in Finnish by Owners of Dogs with Chronic Signs of Pain Caused by Osteoarthritis. *American Journal of Veterinary Research*. 70 (2009) 727-734.
- [6] M. Epstien. Assessing Chronic Pain In Dogs. *Today's Veterinary Practice*. (2013).
- [7] D. Brown, R. Boston, J. Coyne, J. Farrar. Ability of the Canine Brief Pain Inventory to Detect Response to Treatment in Dogs with Osteoarthritis. *Journal of the American Veterinary Medical Association*. 233 (2008) 1278-83.
- [8] D. Brown, R. Boston, J. Coyne, J. Farrar. Development and Psychometric Testing of an Instrument Designed to Measure Chronic Pain in Dogs with Osteoarthritis. *American Journal of Veterinary Research*. 68 (2007) 631-37.